Oncological Follow-up with 2-[ 18 F]-FDG PET/CT in Li-Fraumeni Syndrome
| Autor: | Hernandez MA; Autonomous University of Bucaramanga (UNAB), Department of Nuclear Medicine, Bucaramanga, Santander, Colombia, Vega Gonzalez IF; Las Américas Clinic Auna, Department of Nuclear Medicine, Medellin, Antioquia, Colombia, Vélez LL; Las Américas Clinic Auna, Department of Nuclear Medicine, Medellin, Antioquia, Colombia, Arango CM; Las Américas Clinic Auna, Department of Radiology, Medellin, Antioquia, Colombia |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Molecular imaging and radionuclide therapy [Mol Imaging Radionucl Ther] 2021 Jun 03; Vol. 30 (2), pp. 110-112. |
| DOI: | 10.4274/mirt.galenos.2020.33255 |
| Abstrakt: | Li-Fraumeni syndrome is a rare disorder caused by abnormalities of the tumor-suppressor protein P53 gene. We present the case of a 26-years-old female diagnosed with bilateral ductal carcinoma. The genetic panel for breast cancer gene 1 (BRCA1) and BRCA2 mutations was negative and positive heterozygous germline tumor protein P53 gene mutations, considering Li-Fraumeni syndrome. A 2-[ 18 F]-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) was used for postsurgical staging to show the right lung hypermetabolic nodule. A lobectomy was accomplished, and histopathology reported pulmonary adenocarcinoma. A year later, oncological follow-up was conducted with 2-[ 18 F]-FDG PET/CT without evidence of abnormalities. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|